Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors

Cancer Causes and Control

Volumn 27, Issue 6, 2016, Pages 737-748

  Merritt, Melissa A ^a   Strickler, Howard D ^b   Einstein, Mark H ^b   Yang, Hannah P ^c   Sherman, Mark E ^c   Wentzensen, Nicolas ^c   Brouwer Visser, Jurriaan ^b   Cossio, Maria Jose ^b   Whitney, Kathleen D ^b   Yu, Herbert ^d   Gunter, Marc J ^a   Huang, Gloria S ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Endometrial cancer; Endometrium; Estrogen receptor; Insulin; Insulin like growth factor

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; IGF1R PROTEIN, HUMAN; IGF2 PROTEIN, HUMAN; IGFBP1 PROTEIN, HUMAN; IGFBP3 PROTEIN, HUMAN; INSULIN; INSULIN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROGESTERONE RECEPTOR; PTEN PROTEIN, HUMAN; SEX HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

ADULT; AGED; DIABETES MELLITUS; ENDOMETRIUM; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PARITY; POSTMENOPAUSE; PREMENOPAUSE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; AGED; DIABETES MELLITUS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION; GONADAL STEROID HORMONES; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; PARITY; PHOSPHOPROTEINS; POSTMENOPAUSE; PREMENOPAUSE; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INSULIN; RECEPTORS, PROGESTERONE; RECEPTORS, SOMATOMEDIN; RISK FACTORS; RNA, MESSENGER;

EID: 84964412346     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-016-0751-4     Document Type: Article

References (50)

1. Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11, Lyon, France
2. World Cancer Research Fund/American Institute for Cancer Research (2013) Continuous update project report. Food, Nutrition, Physical Activity, and the Prevention of Endometrial Cancer
3. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384(9945):755–765
4. Arnold M, Pandeya N, Byrnes G et al (2015) Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 16(1):36–46
5. Liao C, Zhang D, Mungo C, Andrew TD, Zeidan AM (2014) Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol 135(1):163–171
6. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85(2):304–313
7. Yang HP, Wentzensen N, Trabert B et al (2013) Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol 177(2):142–151
8. Dossus L, Allen N, Kaaks R et al (2010) Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 127(2):442–451
9. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM (2013) Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case–control study, systematic review and meta-analysis. Int J Cancer 132(5):1146–1155
10. Argenta P, Svendsen C, Elishaev E et al (2014) Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. Gynecol Oncol 133(1):78–82
11. Yang HP, Meeker A, Guido R et al (2015) PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes Control (published online: 1–8)
12. Rutanen EM (1998) Insulin-like growth factors in endometrial function. Gynecol Endocrinol 12(6):399–406
13. Zhu L, Pollard JW (2007) Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proc Natl Acad Sci USA 104(40):15847–15851
14. Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev 11(12):1531–1543
15. Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57(2):205–212
16. Longcope C, Pratt JH, Schneider SH, Fineberg SE (1978) Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 46(1):146–152
17. Perel E, Killinger DW (1979) The interconversion and aromatization of androgens by human adipose tissue. J Steroid Biochem 10(6):623–627
18. Lukanova A, Lundin E, Micheli A et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108(3):425–432
19. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159–169
20. Cust AE, Allen NE, Rinaldi S et al (2007) Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer 120(12):2656–2664
21. Gunter MJ, Hoover DR, Yu H et al (2008) A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev 17(4):921–929
22. Lukanova A, Zeleniuch-Jacquotte A, Lundin E et al (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108(2):262–268
23. Brouwer-Visser J, Huang GS (2015) IGF2 signaling and regulation in cancer. Cytokine Growth Factor Rev 26(3):371–377
24. Matias-Guiu X, Prat J (2013) Molecular pathology of endometrial carcinoma. Histopathology 62(1):111–123
25. Mutter GL, Lin MC, Fitzgerald JT et al (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92(11):924–930
26. Lacey JV Jr, Mutter GL, Ronnett BM et al (2008) PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 68(14):6014–6020
27. Sarfstein R, Werner H (2013) Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 154(5):1672–1679
28. Lotan TL, Gurel B, Sutcliffe S et al (2011) PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17(20):6563–6573
29. Brouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y, Huang GS (2014) Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PLoS One 9(6):e100165
30. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408
31. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr (1989) Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 49(4):1052–1056
32. McCampbell AS, Broaddus RR, Loose DS, Davies PJ (2006) Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 12(21):6373–6378
33. R Core Team (2012) R: a language and environment for statistical computing. Vienna, Austria
34. Garofalo C, Mancarella C, Grilli A et al (2012) Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing’s sarcoma. Mol Endocrinol 26(9):1603–1616
35. Aleksic T, Chitnis MM, Perestenko OV et al (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70(16):6412–6419
36. Kim JJ, Kurita T, Bulun SE (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34(1):130–162
37. Loverro G, Perlino E, Maiorano E et al (1999) TGF-beta 1 and IGF-1 expression in atrophic post-menopausal endometrium. Maturitas 31(2):179–184
38. Leone M, Costantini C, Gallo G et al (1993) Role of growth factors in the human endometrium during aging. Maturitas 16(1):31–38
39. O’Toole SA, Dunn E, Sheppard BL et al (2005) Oestrogen regulated gene expression in normal and malignant endometrial tissue. Maturitas 51(2):187–198
40. Evans LH, Martin JD, Hahnel R (1974) Estrogen receptor concentration in normal and pathological human uterine tissues. J Clin Endocrinol Metab 38(1):23–32
41. Scharl A, Vierbuchen M, Graupner J, Fischer R, Bolte A (1988) Immunohistochemical study of distribution of estrogen receptors in corpus and cervix uteri. Arch Gynecol Obstet 241(4):221–233
42. Press MF, Nousek-Goebl N, King WJ, Herbst AL, Greene GL (1984) Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. Lab Invest 51(5):495–503
43. Mylonas I, Jeschke U, Shabani N et al (2007) Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 22(2):169–176
44. Sivridis E, Giatromanolaki A (2004) Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. J Clin Pathol 57(8):840–844
45. Giudice LC, Mark SP, Irwin JC (1998) Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface. J Reprod Immunol 39(1–2):133–148
46. Rutanen EM (2000) Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery. Hum Reprod 15(Suppl 3):173–181
47. Amso NN, Crow J, Shaw RW (1994) Comparative immunohistochemical study of oestrogen and progesterone receptors in the fallopian tube and uterus at different stages of the menstrual cycle and the menopause. Hum Reprod 9(6):1027–1037
48. Press MF, Udove JA, Greene GL (1988) Progesterone receptor distribution in the human endometrium. Analysis using monoclonal antibodies to the human progesterone receptor. Am J Pathol 131(1):112–124
49. Snijders MP, de Goeij AF, Debets-Te Baerts MJ, Rousch MJ, Koudstaal J, Bosman FT (1992) Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil 94(2):363–371
50. Giudice LC, Lamson G, Rosenfeld RG, Irwin JC (1991) Insulin-like growth factor-II (IGF-II) and IGF binding proteins in human endometrium. Ann NY Acad Sci 626:295–307